Skip to content
DataLookout
Menu

SEMA AUDNCT07772960

Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 4 more changesShow less
    • Eligibility criteria expanded, about 17 words
    • Study sites: 1 to 2
    • Secondary endpoints: details revised at 1 of 3 entries
    • Publications: details revised at 1 of 1 entry
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Alcohol use days
Timeframe: 20 weeks

Secondary (3)

Heavy drinking days
Average drinks per drinking day
Obsessive Compulsive Drinking Scale (OCDS) to assess Alcohol craving

Arms and interventions

PlaceboPlacebo comparator

Placebo saline pen administered weekly for 20 weeks

Semaglutide 1.0 mgActive comparator

Semaglutide low dose of 1.0 mg administered weekly over the 20-weeks trial

Semaglutide 2.0 mgActive comparator

Semaglutide high dose 2.0 mg administered weekly over the 20-weeks trial

Other: Placebo

Drugs: Semaglutide 1.0 mg, Semaglutide 2.0 mg

Sites

2 sites in 1 country